European equities traded in the US as American depositary receipts opened the week higher late Monday morning, rising 0.94% to 1,560.11 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion (EVAX), which climbed 9.2% and 3.4%, respectively. They were followed by semiconductor company Sequans Communications (SQNS) and 3D printer company Materialise (MTLS), which advanced 2.7% and 2.4%, respectively.

The decliners from continental Europe were led by biopharmaceutical company Genfit (GNFT) and telecommunications company Nokia (NOK), which fell 1.5% each. They were followed by internet advertising firm Criteo (CRTO) and medical device maker EDAP TMS (EDAP), which lost 1.4% and 1%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies NuCana (NCNA) and Adaptimmune Therapeutics (ADAP), which surged 15% and 10%, respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Amarin (AMRN), which rose 5.4% and 5.2%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotech company Trinity (TRIB), which dropped 15% and 4.8%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and tobacco company British American Tobacco (BTI), which were down 2.8% and 1.3%, respectively.